Commonwealth Fund July 30, 2021
Kristi Martin


President Biden signed an executive order to promote competition in prescription drug markets — a move aimed at lowering drug costs

The order lays out actions for federal agencies to address anticompetitive behaviors of drug manufacturers and explore tactics to increase the use of generic drugs and biosimilars

Earlier this month, President Biden signed an executive order, Promoting Competition in the American Economy. The order lays out actions to address consolidation in health care markets and price competition in the prescription drug markets. The administration has indicated that lowering drug prices is a priority and instructed agencies to act. In addition, Congress is working to move drug pricing reform this year. A comprehensive approach is needed that focuses on...

Today's Sponsors

Canton & Company

Today's Sponsors


Today's Sponsor

Crossover Health

Topics: Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
Treatment for all: the key steps to better representation in pharma
Can We Tik-Tok Our Way Out of a Pandemic? A Q&A about Gen Z Influencers, and Where Pharma Can Go Next
Psychedelic drugs, but safer: Delix raises $70M to bring new neuro meds to clinic
Retail pharmacies: The key to making clinical trials accessible for everybody?
Generic drug companies want to help make the COVID-19 vaccines